Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Derrick Gingery

Senior Writer

Washington, DC
Senior writer Derrick Gingery has been reporting on regulatory issues for "The Pink Sheet" and "The Pink Sheet" Daily since 2010. Among his favorite topics are FDA's user fee programs, along with generic drug and biosimilar policy, but he also handles drug approval issues and general FDA news.

An award-winning journalist, Derrick has written extensively about user fee negotiations, the FDA budget, FDA travel restrictions and drug advertising compliance. He also was part of the Pink Sheet team covering FDA's first biosimilar advisory committee meetings.

When he's not following FDA, Derrick is keeping close tabs on Indiana Hoosiers basketball.
Advertisement
Set Alert for Articles By Derrick Gingery

Latest From Derrick Gingery

Gottlieb Advances, But FDA's Future Seems Increasingly Partisan

Senate committee votes to send the FDA Commissioner nominee to the Senate floor, but with only two Democratic votes.

FDA Leadership

US FDA Still Waiting For Cures Money, Woodcock Says

When asked about Cures-related hiring, the FDA drug-center director says to her knowledge, no funding has been received yet.

FDA Policy

Gottlieb Confirmation: Scheduling, Paperwork Delay Committee Vote One Day

FDA Commissioner nominee's answers to questions about his confidential committee paperwork did not arrive until minutes before the committee hearing, but Republicans' scheduling conflicts also may be to blame for the delay.

FDA Leadership

US FDA Still Waiting For Cures Money, Woodcock Says

When asked about Cures-related hiring, CDER Director says to her knowledge, no funding has been received yet.

FDA Legislation

Flu Hunters: House Committee Searches For Pandemic Plan

Update to 2005 outline of US response to pandemic influenza was due at the end of 2016, but has yet to be released.

FDA Research & Development

Label Expansion: Could Clinical Experience Data Find Supplement Work-Around?

Friends of Cancer Research seeks way of allowing high-quality efficacy data into label when supplemental NDA is not feasible.

FDA Review Pathway
See All
Advertisement
UsernamePublicRestriction

Register